Intergroup's 15-min chart triggers RSI overbought, Bollinger bands narrowing.

The 15-minute chart for the Intergroup indicates that the Relative Strength Index has reached an overbought level, while the Bollinger Bands have narrowed on July 10, 2025 at 14:15. This suggests that the stock price has risen at an accelerated pace, potentially exceeding its fundamental value support, and the magnitude of price fluctuations has decreased.

Sonoma Pharmaceuticals, Inc. (SNOA), a company specializing in innovative healthcare solutions through its patented Microcyn® technology, has recently expanded its market reach by registering its manufacturing facility and listing a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act (MoCRA). This move allows the company to manufacture and commercialize its Microcyn technology products as cosmetics in the U.S., thereby increasing access to the U.S. cosmetics and dermatology consumer markets.

The registration under MoCRA enables Sonoma Pharmaceuticals to position itself for growth in the U.S. market, which is projected to reach nearly $40 billion by 2030. This strategic move follows a series of regulatory milestones and product launches, including the successful registration of its manufacturing facility and various products under the MHRA in the United Kingdom. The company's portfolio includes stabilized hypochlorous acid (HOCl) products for wound care, dermatology, and animal health, demonstrating its commitment to non-toxic, evidence-based therapies.

Sonoma Pharmaceuticals has also been actively engaging with the investment community. The company recently participated in the Lytham Partners Fall 2025 Investor Conference, where management provided updates on its financial performance and strategic initiatives. Additionally, the company received the National Psoriasis Foundation (NPF) Seal of Recognition for its Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel, further validating the efficacy and safety of its products for people with chronic skin conditions.

The company's financial results for the first quarter of fiscal year 2026 showed significant growth, with total revenue reaching $4.0 million, an 18% increase year-over-year. This growth was driven by strong performance in key markets, including a 57% increase in U.S. revenue and a 14% growth in European revenue. Despite the revenue growth, the company reported a net loss of $1.2 million and held cash reserves of $3.6 million as of June 30, 2025.

Sonoma Pharmaceuticals' expansion into the U.S. cosmetics market, combined with its strong financial performance and regulatory achievements, positions the company for continued growth and innovation in the healthcare sector.